2-(2-bromophenyl)-2,2-difluoroacetic acid | 1375472-90-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2-bromophenyl)-2,2-difluoroacetic acid
• CAS: 1375472-90-4
• 化学式: C₈H₅BrF₂O₂
• mdl: MFCD21602517
• 分子量: 251.027
• InChiKey: ALUGEFZIOIIHCE-UHFFFAOYSA-N

物化性质

• 沸点：
  307.6±37.0 °C(Predicted)
• 密度：
  1.733±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(2-bromophenyl)-2,2-difluoroacetic acid 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以450 mg的产率得到2-(2-bromophenyl)-2,2-difluoroacetyl chloride
  参考文献：
  名称：

  [EN] NOVEL SUBSTITUTED N'-HYDROXYCARBAMIMIDOYL-1,2,5-OXADIAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS
  [FR] NOUVEAUX COMPOSÉS DE N'-HYDROXYCARBAMIMIDOYL -1,2,5-OXADIAZOLE SUBSTITUÉS EN TANT QU'INHIBITEURS DE L'INDOLÉAMINE 2,3-DIOXYGÉNASE (IDO)

  摘要：

  本文揭示了化合物的化学式(I)，或其药学上可接受的盐：化学式(I)。本文还揭示了所述化合物在潜在治疗或预防IDO相关疾病或紊乱中的用途。本文还揭示了包含所述化合物的组合物。本文还揭示了所述组合物在潜在治疗或预防IDO相关疾病或紊乱中的用途。

  公开号：

  WO2018044663A1
• 作为产物：
  描述：

  2-(2-溴苯基)-2,2-二氟乙酸乙酯 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 12.0h， 生成 2-(2-bromophenyl)-2,2-difluoroacetic acid
  参考文献：
  名称：

  银催化的α，α-二氟芳基丙烯酸的脱羧自由基烯丙基化反应，用于构建CF2-烯丙基键

  摘要：

  已经开发出一种有效的银催化的α，α-二氟芳基羧酸的脱羧自由基烯丙基化以建立CF 2-烯丙基键的方法。使用烯丙基砜作为烯丙基供体，成功地将带有各种官能团的α，α-二氟取代的芳基丙烯酸烯丙基化，以中度至优异的产率在CH 3水溶液中获得一系列3-（α，α-二氟苄基）-1-丙烯化合物在温和条件下的CN溶液。实验研究表明，芳基乙酸的α-氟取代对自由基活性和反应性有很大影响。

  DOI：

  10.1039/d0ob02546a

文献信息

• Synthesis of Difluoroalkylated Arenes by Hydroaryldifluoromethylation of Alkenes with α,α-Difluoroarylacetic Acids under Photoredox Catalysis
  作者：Bin Yang、Xiu-Hua Xu、Feng-Ling Qing

  DOI：10.1021/acs.orglett.6b03092

  日期：2016.11.18

  A visble-light-induced hydroaryldifluoromethylation of alkenes with α,α-difluoroarylacetic acids for preparation of difluoroalkylated arenes has been developed. This reaction proceeds through the hypervalent iodine reagent promoted decarboxylation and subsequent radical hydroaryldifluoromethylation.

  已经开发了可见光诱导的烯烃与α，α-二氟芳基丙烯酸的烯烃的氢化芳基二氟甲基化，以制备二氟烷基化的芳烃。该反应通过高价碘试剂促进的脱羧作用和随后的自由基氢芳基二氟甲基化而进行。
• Substituted n′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10988487B2

  公开（公告）日：2021-04-27

  Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

  本文公开了一种式 (I) 的化合物或其药学上可接受的盐：式 (I)。本文还公开了本文公开的化合物在潜在治疗或预防 IDO 相关疾病或紊乱中的用途。本文还公开了包含本文公开的化合物的组合物。本文进一步公开了这些组合物在潜在治疗或预防 IDO 相关疾病或紊乱中的用途。
• Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy
  作者：Hongjun Zhang、Kun Liu、Qinglin Pu、Abdelghani Achab、Michael J. Ardolino、Mangeng Cheng、Yongqi Deng、Amy C. Doty、Heidi Ferguson、Xavier Fradera、Ian Knemeyer、Ravi Kurukulasuriya、Yu-hong Lam、Charles A. Lesburg、Theodore A. Martinot、Meredeth A. McGowan、J. Richard Miller、Karin Otte、Purakattle J. Biju、Nunzio Sciammetta、Nicolas Solban、Wensheng Yu、Hua Zhou、Xiao Wang、David Jonathan Bennett、Yongxin Han

  DOI：10.1021/acsmedchemlett.9b00344

  日期：2019.11.14

  Checkpoint inhibitors have demonstrated unprecedented efficacy and are evolving to become standard of care for certain types of cancers. However, low overall response rates often hamper the broad utility and potential of these breakthrough therapies. Combination therapy strategies are currently under intensive investigation in the clinic, including the combination of PD-1/PD-L1 agents with IDO1 inhibitors. Here, we report the discovery of a class of IDO1 heme-binding inhibitors featuring a unique amino-cyclobutarene motif, which was discovered through SBDD from a known and weakly active inhibitor. Subsequent optimization efforts focused on improving metabolic stability and were greatly accelerated by utilizing a robust SNAr reaction of a facile nitro-furazan intermediate to quickly explore different polar side chains. As a culmination of these efforts, compound 16 was identified and demonstrated a favorable overall profile with superior potency and selectivity. Extensive studies confirmed the chemical stability and drug-like properties of compound 16, rendering it a potential drug candidate.
• Visible-Light-Induced Cascade Cyclization of 1-Acryloyl-2-cyanoindole: Access of Difluoroalkylated Pyrrolo[1,2-<i>a</i>]indolediones
  作者：Jinwei Yuan、Lu Shen、Na Guo、Yanli Yin、Pengyuan Yang、Liangru Yang、Yongmei Xiao、Shouren Zhang

  DOI：10.1021/acs.joc.3c02183

  日期：2023.12.1
• 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
  申请人：Aventis Pharmaceuticals Inc.

  公开号：EP1891019A2

  公开（公告）日：2008-02-27